Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis

Kotyla, Przemysław; Islam, Asiful; Engelmann, Małgorzata

doi:10.3390/ijms21197390

Cited by 32 publications

(42 citation statements)

References 93 publications

(111 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19,20 This is also an effect of the drug class. [21][22][23] Importantly, for those patients with UC, it was further reported that there were minimal changes in total cholesterol: high-density lipoprotein-cholesterol or low-density lipoprotein-cholesterol: high-density lipoprotein-cholesterol ratios, and increases in lipids were associated with reduced systemic inflammation.…”

Section: Discussionmentioning

confidence: 99%

Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies

Lees

Deuring

Chiorean³

et al. 2021

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Introduction: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Outcome prediction based on early treatment response, along with clinical and laboratory variables, would be very useful for clinical practice. The aim of this study was to determine early variables predictive of responder status in patients with UC treated with tofacitinib. Methods: Data were collected from patients treated with tofacitinib 10 mg twice daily in the OCTAVE Induction 1 and 2 studies (NCT01465763 and NCT01458951). Logistic regression and random forest analyses were performed to determine the power of clinical and/or laboratory variables to predict 2- and 3-point partial Mayo score responder status of patients at Weeks 4 or 8 after baseline. Results: From a complete list of variables measured in OCTAVE Induction 1 and 2, analyses identified partial Mayo score, partial Mayo subscore (stool frequency, rectal bleeding, and Physician Global Assessment), cholesterol level, and C-reactive protein level as sufficient variables to predict responder status. Using these variables at baseline and Week 2 predicted responder status at Week 4 with 84–87% accuracy and Week 8 with 74–79% accuracy. Variables at baseline, Weeks 2 and 4 could predict responder status at Week 8 with 85–87% accuracy. Conclusion: Using a limited set of time-dependent variables, statistical and machine learning models enabled early and clinically meaningful predictions of tofacitinib treatment outcomes in patients with moderately to severely active UC.

show abstract

Section: Discussionmentioning

confidence: 99%

Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies

Lees

Deuring

Chiorean³

et al. 2021

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…The signaling cascade occurs through the communication between cytokines and class I and II receptors in the cell membrane, causing activation of JAKs [ 60 ], which phosphorylate and allow the fitting with STAT proteins, which are also phosphorylated. Thus, STAT multidimers can promote epigenetic changes by regulating gene transcription in the nucleus [ 61 , 62 ]. Considering the JAK/STAT pathway, most hydrolyzed proteins and peptides acted by minimizing this activation cascade.…”

Section: Metabolic Pathways Of Inflammation In Obesity: Potential The...mentioning

confidence: 99%

Hydrolyzed Proteins and Vegetable Peptides: Anti-Inflammatory Mechanisms in Obesity and Potential Therapeutic Targets

et al. 2022

View full text Add to dashboard Cite

Chronic low-grade inflammation is present in overweight and obesity, causing changes in several metabolic pathways. It impairs systemic functioning and positively feeds back the accumulation of more adipose tissue. Studies with hydrolyzed proteins and plant peptides have demonstrated a potential anti-inflammatory and immunomodulatory effect of these peptides. However, it is challenging and necessary to explore the mechanism of action of such molecules because understanding their effects depends on their structural characterizations. Furthermore, the structure might also give insights into safety, efficacy and efficiency, with a view of a possible health application. Thus, the present narrative review aimed to discuss the mechanisms of action of hydrolyzed proteins and plant peptides as anti-inflammatory agents in obesity. Keywords and related terms were inserted into databases for the search. Based on the studies evaluated, these biomolecules act by different pathways, favoring the reduction of inflammatory cytokines and adipokines and the polarization of macrophages to the M2 phenotype. Finally, as a future perspective, bioinformatics is suggested as a tool to help understand and better use these molecules considering their applicability in pre-clinical and clinical studies.

show abstract

“…RA has a global prevalence of around 1% with the incidence in women being 2–3 fold more than in men. In addition, RA is associated with an increased risk of internal organ damage and systemic complications, with premature atherosclerosis being the most important [ 8 , 9 , 10 , 11 ]. According to the WHO, three out of five people worldwide die from diseases associated with chronic inflammatory diseases such as stroke, chronic respiratory diseases, heart disorders, obesity, and diabetes.…”

Section: Introductionmentioning

confidence: 99%

Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems

Plachá

Jampílek

2021

Pharmaceutics

View full text Add to dashboard Cite

Inflammatory diseases, whether caused by excessive stress on certain tissues/parts of the body or arising from infections accompanying autoimmune or secondary diseases, have become a problem, especially in the Western world today. Whether these are inflammations of visceral organs, joints, bones, or the like, they are always a physiological reaction of the body, which always tries to eradicate noxious agents and restore tissue homeostasis. Unfortunately, this often results in damage, often irreversible, to the affected tissues. Nevertheless, these inflammatory reactions of the body are the results of excessive stress, strain, and the generally unhealthy environment, in which the people of Western civilization live. The pathophysiology and pathobiochemistry of inflammatory/autoimmune processes are being studied in deep detail, and pharmaceutical companies are constantly developing new drugs that modulate/suppress inflammatory responses and endogenous pro-inflammatory agents. In addition to new specifically targeted drugs for a variety of pro-inflammatory agents, a strategy can be found for the use of older drugs, which are formulated into special nanodrug delivery systems with targeted distribution and often modified release. This contribution summarizes the current state of research and development of nanoformulated anti-inflammatory agents from both conventional drug classes and experimental drugs or dietary supplements used to alleviate inflammatory reactions.

show abstract

Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis

Cited by 32 publications

References 93 publications

Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies

Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies

Hydrolyzed Proteins and Vegetable Peptides: Anti-Inflammatory Mechanisms in Obesity and Potential Therapeutic Targets

Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems

Contact Info

Product

Resources

About